Llwytho...

Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia

Approved therapies that target the B-cell receptor (BCR) signaling pathway, such as ibrutinib and idelalisib, are known to show activity in chronic lymphocytic leukemia (CLL) via their direct effects on crucial survival pathways in malignant B cells. However, these therapies also have effects on T c...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood Adv
Prif Awduron: Maharaj, Kamira, Sahakian, Eva, Pinilla-Ibarz, Javier
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2017
Pynciau:
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728096/
https://ncbi.nlm.nih.gov/pubmed/29296833
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017006809
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!